Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000073-21
    Sponsor's Protocol Code Number:BH29992
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-03-18
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-000073-21
    A.3Full title of the trial
    A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS
    ENSAYO CLÍNICO DE FASE III MULTICÉNTRICO, ABIERTO Y DE UN SOLO BRAZO PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA FARMACOCINÉTICA DE LA ADMINISTRACIÓN SUBCUTÁNEA DE EMICIZUMAB UNA VEZ A LA SEMANA EN PACIENTES PEDIÁTRICOS CON HEMOFILIA A CON INHIBIDORES
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Emicizumab in Hemophilia A Pediatric Patients With Inhibitors
    Estudio Fase III para evaluar la Eficacia, Seguridad y Farmacocinética de Emicizumab en pacientes pediatricos con hemofilia A con inhibidores
    A.4.1Sponsor's protocol code numberBH29992
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorRoche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann-La Roche Ltd
    B.4.2CountrySwitzerland
    B.4.1Name of organisation providing supportChugai Pharmaceutical Co. Ltd
    B.4.2CountryJapan
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF.Hoffmann-La Roche Ltd
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number+34913257300
    B.5.6E-mailglobal.rochegenentechtrials@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/13/1221
    D.3 Description of the IMP
    D.3.1Product nameACE910
    D.3.2Product code RO5534262
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEmicizumab
    D.3.9.2Current sponsor codeRo 553-4262/F03
    D.3.9.3Other descriptive nameRO5534262 EMICIZUMAB
    D.3.9.4EV Substance CodeSUB168081
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeRO5534262 (ACE910) is a recombinant humanized anti-activated blood coagulation Factor IX (anti-FIXa) and anti-blood coagulation Factor X (anti-FX) bispecific monoclonal antibody
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/13/1221
    D.3 Description of the IMP
    D.3.1Product nameACE910
    D.3.2Product code RO5534262
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEmicizumab
    D.3.9.2Current sponsor codeRo 553-4262/F03
    D.3.9.3Other descriptive nameRO5534262 EMICIZUMAB
    D.3.9.4EV Substance CodeSUB168081
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeRO5534262 (ACE910) is a recombinant humanized anti-activated blood coagulation Factor IX (anti-FIXa) and anti-blood coagulation Factor X (anti-FX) bispecific monoclonal antibody
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/13/1221
    D.3 Description of the IMP
    D.3.1Product nameACE910
    D.3.2Product code RO5534262
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEmicizumab
    D.3.9.2Current sponsor codeRo 553-4262/F03
    D.3.9.3Other descriptive nameRO5534262 EMICIZUMAB
    D.3.9.4EV Substance CodeSUB168081
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeRO5534262 (ACE910) is a recombinant humanized anti-activated blood coagulation Factor IX (anti-FIXa) and anti-blood coagulation Factor X (anti-FX) bispecific monoclonal antibody
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Hemophilia A with Inhibitors
    Hemofilia A con inhibidores
    E.1.1.1Medical condition in easily understood language
    Hemophilia A is a genetic deficiency in blood clotting factor VIII, which causes increased bleeding. Inhibitors, however, prevent replacement factor VIII concentrates from controlling bleeds.
    Hemofilia A es una deficiencia genética en la coagulación del Factor VIII de la sangre que provoca un aumento de los sangrados. Los inhibidores impiden el reemplazo de los concentrados de Factor VIII
    E.1.1.2Therapeutic area Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level LLT
    E.1.2Classification code 10053753
    E.1.2Term Hemophilia A without inhibitors
    E.1.2System Organ Class 100000004850
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    There is no formal hypothesis testing in the study.
    Efficacy
    ? To evaluate clinical effect of prophylactic emicizumab on number of bleeds over time (bleed rate)
    ? To characterize efficacy of up-titration on both intra-patient and population level, also on the basis of the number of bleeds over time
    ? To evaluate Health-Related Quality of Life (HRQoL) of children 8-17 years of age according to Hemophilia-Specific Quality of Life Index (Haemo-QoL) Short Form (SF) (completed by patients)
    ? To evaluate proxy-reported HRQoL and aspects of caregiver burden using the Adapted inhibitor-specific questionnaire for the assessment of health-related quality of life (InhibQoL) including aspects of caregiver burden questionnaire for all children (completed by caregivers)
    ? To assess number of days away from day care/preschool/school and days hospitalized
    No hay una hipótesis formal en este estudio.
    Eficacia
    -Evaluar el efecto clínico del tratamiento profiláctico con emicizumab en el número de hemorragias ocurridas a lo largo del tiempo (la frecuencia de hemorragias).
    -Caracterizar la eficacia del aumento de la dosis en pacientes individuales y en la población del estudio, también en función del número de hemorragias ocurridas a lo largo del tiempo
    -Evaluar la calidad de vida relacionada con la salud (CdVRS) en niños de 8 a 17 años de edad utilizando el Cuestionario abreviado Haemo-QoL_Short Form (SF) (cumplimentado por los pacientes).
    -Evaluar en todos los niños la CdVRS en opinión de un allegado y aspectos relacionados con la carga para el cuidador utilizando el cuestionario InhibQoL adaptado (cumplimentado por los cuidadores).
    -Determinar el número de días que los niños faltan a la guardería/centro preescolar/colegio y el número de días que están hospitalizados.
    E.2.2Secondary objectives of the trial
    There is no formal hypothesis testing in the study.
    Safety:
    ? To evaluate overall safety of emicizumab
    Pharmacokinetic:
    ? To characterize the exposure [minimum observed analyte concentration (Ctrough)] of emicizumab in patients prior to drug administration
    Pharmacodynamics:
    ? To assess potential pharmacodynamic (PD) biomarkers of emicizumab, including but not limited to activated partial thromboplastin time (aPTT) and FVIII activity
    No hay una hipótesis formal en este estudio.
    Seguridad:
    -Evaluar la seguridad global de emicizumab
    Farmacocinética:
    -Caracterizar la exposición (Cmínima) a emicizumab en pacientes antes de la administración del fármaco el día 1
    Farmacodinamia:
    -Evaluar los posibles biomarcadores FD de emicizumab, entre otros la actividad de TTPa y FVIII.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    -Children < 12 years of age at time of informed consent with allowance for the following: for patients 12-17 years of age and who weigh < 40 kilograms (kg) at the time of informed consent; and for patients < 2 years of age will be allowed to participate only after the protocol defined interim data review criteria are met
    - Body weight > 3 kg
    - Caregivers must have the willingness and ability to comply with all study procedures
    - Diagnosis of congenital hemophilia A of any severity and documented history of high-titer inhibitor
    - Requires treatment with bypassing agents
    - For patients >= 2 years of age: if on episodic bypassing agent regimen annualized bleeding rate (ABR) of >=6 ; or if on prophylactic bypassing agent regimen inadequately controlled or central venous access device (CVAD) placement medically not feasible or deemed unsafe
    - For patients < 2 years of age determined by investigator to be in high unmet medical need
    - Adequate hematologic function as platelet count of >=100 x 10*9 cells/Liter (L) and hemoglobin >= 8 gram (g)/deciliter (dL) (4.97 millimoles/L) at the time of screening
    - Adequate hepatic and renal function
    - Female patients of childbearing potential who have negative serum pregnancy test result and an agreement to remain abstinent or use contraceptive methods specified in the study
    -Niños < 12 años de edad en el momento de obtener el consentimiento informado y además:
    Pacientes de 12 a 17 años de edad que pesen < 40 kg en el momento del consentimiento informado;
    Podrán participar pacientes < 2 años de edad únicamente después de cumplir los criterios establecidos en el protocolo para el análisis intermedio de los datos.
    -Peso corporal > 3 kg
    -Los cuidadores de todos los niños deberán tener la voluntad y posibilidad de cumplir con todos los procedimientos del estudio
    -Diagnóstico de hemofilia A congénita de cualquier intensidad y antecedentes documentados de títulos altos de inhibidores
    -Necesidad de tratamiento con agentes by pass
    -En pacientes ? 2 años de edad:
    Si reciben un régimen de agentes by pass episódicos: ABR de ? 6; O si reciben un régimen profiláctico con agentes by pass: control insuficiente o imposibilidad de colocar un dispositivo de acceso venoso central (DAVC) por motivos médicos o porque el investigador lo considere poco seguro.
    -En pacientes < 2 años de edad: que el investigador considere que existe una necesidad médica importante no atendida
    -Función hematológica adecuada, definida como un recuento de plaquetas ? 100 x 109 células/l y hemoglobina ? 8 g/dl (4,97 mmol/l) en el momento de la selección
    -Función hepática y renal adecuada
    -Mujeres en edad fértil que tengan un resultado negativo en la prueba de embarazo en suero y que se comprometen a no mantener relaciones sexuales o a utilizar métodos anticonceptivos especificados en el estudio.
    E.4Principal exclusion criteria
    - Inherited or acquired bleeding disorder other than hemophilia A
    - Ongoing or plan to receive immune tolerance induction (ITI) therapy or prophylaxis treatment with FVIII during the study. Patients awaiting initiation of ITI will be eligible and patients in whom ITI has failed will be eligible with a 72-hour washout period prior to the first emicizumab administration
    - Previous (in the past 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
    - Other diseases (i.e., certain autoimmune diseases [e.g., systemic lupus erythematosus], cardiovascular disease) that may increase risk of bleeding or thrombosis
    - Known infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus
    - Use of systemic immunomodulators (e.g., interferon or corticosteroids) at enrolment or planned use during the study period
    - Planned surgery (excluding minor procedures such as tooth extraction or incision and drainage) during the study
    -Trastorno hemorrágico congénito o adquirido distinto de hemofilia A
    -Tratamiento actual (o previsto durante el estudio) de inducción de tolerancia inmunitaria (ITI) o tratamiento profiláctico con FVIII durante el estudio.
    Podrán participar pacientes a la espera de iniciar un tratamiento ITI
    Podrán participar pacientes que no hayan respondido a un tratamiento ITI, con un período de descanso farmacológico de 72 horas antes de la administración de la primera dosis de emicizumab.
    -Tratamiento administrado en el pasado (en los últimos 12 meses) o en el presente para enfermedad tromboembólica (con la excepción de trombosis previa asociada a un catéter que no esté recibiendo en ese momento tratamiento antitrombótico) o signos de enfermedad tromboembólica.
    -Otras enfermedades (esto es, algunas enfermedades autoinmunitarias [p. ej., lupus eritematoso sistémico], enfermedades cardiovasculares) que puedan aumentar el riesgo de hemorragia o trombosis.
    -Infección conocida por el VIH, el virus de la hepatitis B (VHB) o el virus de la hepatitis C (VHC)
    -Uso de inmunomoduladores sistémicos (como interferón o corticosteroides) en el momento del reclutamiento o uso previsto durante el período del estudio
    -Cirugía prevista (excluidos procedimientos menores como extracciones dentales o incisiones y drenajes) durante el estudio
    ?
    E.5 End points
    E.5.1Primary end point(s)
    Efficacy:
    1. Number of bleeds over time
    2. An up-titration on both, an intra-patient and population level
    3. Comparison between historical and on study treatment period for bleed over time
    4. HRQoL of children 8-17 years of age according to Haemo QoL SF (completed by patients)
    5. Proxy-reported HRQoL and aspects of caregiver burden using the adapted InhibQoL Including aspects of caregiver burden questionnaire for all children (completed by caregivers)
    6. Number of days away from day care/preschool/school and days hospitalized
    Eficacia:
    1. Número de hemorragias ocurridas a lo largo del tiempo
    2. Aumento de la dosis en pacientes individuales y en la población del estudio
    3. Comparación de sangrados a lo largo del tiempo entre periodos históricos y de tratamiento del estudio.
    4-Evaluar la calidad de vida relacionada con la salud (CdVRS) en niños de 8 a 17 años de edad utilizando el Cuestionario abreviado Haemo-QoL_Short Form (SF) (cumplimentado por los pacientes).
    5-Evaluar en todos los niños la CdVRS en opinión de un allegado y aspectos relacionados con la carga para el cuidador utilizando el cuestionario InhibQoL adaptado (cumplimentado por los cuidadores).
    6-Determinar el número de días que los niños faltan a la guardería/centro preescolar/colegio y el número de días que están hospitalizados.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Efficacy:
    1-3. Up to 52 weeks
    4-6. Weeks 1, 13, 25, 37, 49, and every 24 weeks from Week 57 up to Week 128
    Eficacia:
    1-3. Hasta un máximo de 52 semanas
    4-6. Semanas 1, 13, 25, 37, 49 y cada 24 semanas desde la semana 57 hasta como máximo la semana 128
    E.5.2Secondary end point(s)
    Safety:
    1. Incidence and severity of adverse events
    2. Incidence and severity of thromboembolic events
    3. Changes in physical examination findings and vital signs
    4. Incidence of laboratory abnormalities
    5. Incidence and severity of injection-site reactions
    6. Incidence of adverse events leading to drug discontinuation
    7. Incidence of severe hypersensitivity, anaphylaxis, and anaphylactoid events
    8. Incidence and clinical significance of anti-emicizumab antibodies
    Pharmacokinetic:
    1. Ctrough of emicizumab
    Pharmacodynamics:
    1. included but not limited to aPTT FVIII activity
    Seguridad:
    1.Incidencia e intensidad de acontecimientos adversos
    2.Incidencia e intensidad de episodios tromboembólicos
    3.Variación en los resultados de las exploraciones físicas y las constantes vitales
    4.Incidencia de anomalías analíticas
    5.Incidencia e intensidad de reacciones en el lugar de la inyección
    6.Incidencia de acontecimientos adversos que obligan a suspender la medicación
    7.Incidencia de episodios intensos de hipersensibilidad, anafilaxia y reacciones anafilactoides
    8.Incidencia y relevancia clínica de anticuerpos contra emicizumab
    Farmacocinéticos:
    1.Cmínima de emicizumab
    Farmacodinámicos:
    1. Incluyendo pero no limitado a la actividad de TTPa y FVIII,
    E.5.2.1Timepoint(s) of evaluation of this end point
    Safety:
    1-7. Up to 128 weeks
    8. Weeks 1, 5, 17, 33, 49, every 12 weeks starting from Week 57 up to Week 128
    Pharmacokinetic:
    1. Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 49, and every 12 weeks from Week 57 up to Week 128
    Pharmacodynamics:
    1. Weeks 1, 3, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 49, and every 12 weeks from Week 57 up to Week 128
    Seguridad:
    1-7. Hasta un máximo de 128 semanas
    8. Semanas 1, 5, 17, 33, 49 y cada 12 semanas desde la semana 57 hasta como máximo la semana 128
    Farmacocinetica:
    1. Semanas 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 49 y cada 12 semanas desde la semana 57 hasta como máximo la semana 128.
    Farmacodinamia:
    1. Semanas 1, 3, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 49 y cada 12 semanas desde la semana 57 hasta como máximo la semana 128.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    historical bleed rates
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA8
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Costa Rica
    France
    Germany
    Italy
    Japan
    South Africa
    Spain
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of this study is defined as the date when the last patient completes the last safety follow-up visit 24 weeks after discontinuing emicizumab, enrolls in a future separate emicizumab extension study, or is lost to follow-up.
    La finalización de este estudio se define como la fecha en que el último paciente termine la última visita de seguimiento de la seguridad 24 semanas después de discontinuar la administración de emicizumab, participe en otro futuro estudio de extensión de emicizumab o se pierda para el seguimiento.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 40
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 2
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 18
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 20
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state3
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 17
    F.4.2.2In the whole clinical trial 40
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The Sponsor will offer post-trial access to the study drug (RO5534262)
    free of charge to eligible patients in accordance with the Roche Global
    Policy on Continued Access to Investigational Medicinal Product.
    The Roche Global Policy on Continued Access to Investigational
    Medicinal Product is available at the following Web site:
    http://www.roche.com/policy_continued_access_to_investigational_
    medicines.pdf
    El promotor ofrecera acceso después del ensayo al fármaco del estudio (RO5534262) gratuitamente a los pacientes elegibles de acuerdo con la Politica Global de Roche de acceso continuado a los medicamentos en Investigacion. La Politica Global de Roche de acceso continuado a los medicamentos en investigación está disponible en la siguiente página web: http://www.roche.com/policy_continued_access_to_investigational_
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-05-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-05-05
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2020-11-11
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:14:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA